Intracoronary Infusion of Skeletal Myoblasts Improves Cardiac Function in Doxorubicin-Induced Heart Failure

Background—Skeletal myoblast transplantation is promising for the treatment of end-stage heart failure. Direct intramyocardial injection is useful for local cell delivery but may not be effective in global dissemination of cells into the heart, which would be advantageous in treating generalized cardiac dysfunction as in dilated cardiomyopathy. We hypothesized that intracoronary infusion of myoblasts would disseminate cells more effectively, leading to functional improvement in global heart failure. Methods and Results—Heart failure was induced by the intraperitoneal administration of doxorubicin (total dose 15 mg/kg) in rat. One million primary skeletal myoblasts were then infused via the coronary arteries of an excised, failing doxorubicin-treated heart. After incubation under increased intracoronary pressure, the hearts were subsequently transplanted into syngeneic recipients. For the control group, doxorubicin-treated hearts were infused with medium only and transplanted. Four weeks after transplantation, Langendorff perfusion demonstrated that both maximum dP/dt (2797.6±103.3 versus 2326.9±133.1 mm Hg/s, P =0.01) and minimum dP/dt (−2067.4±88.1 versus −1718.8±91.3 mm Hg/s, P =0.02) were improved in myoblast-transplanted hearts compared with medium-infused hearts. This was associated with a sharper slope of the left ventricular developed pressure-volume curve and a reduced slope of the end-diastolic pressure-volume relation in the myoblast-transplanted hearts. Immunohistochemistry for skeletal myosin heavy chain showed that globally disseminated myoblasts had survived and differentiated into multinucleated myotubes that had aligned with the cardiac fiber axis within host myocardium. No significant myocardial infarction was observed. Conclusions—We demonstrated the feasibility and efficiency of skeletal myoblast transplantation via the intracoronary route as a promising strategy for improving cardiac function in global heart failure.

[1]  M. Yacoub,et al.  Heat Shock Treatment Enhances Graft Cell Survival in Skeletal Myoblast Transplantation to the Heart , 2000, Circulation.

[2]  M. Yacoub,et al.  Development of a Novel Method for Cell Transplantation Through the Coronary Artery , 2000, Circulation.

[3]  H. Blau,et al.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.

[4]  A. Hagège,et al.  Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. , 2000, The Journal of thoracic and cardiovascular surgery.

[5]  Doris A Taylor,et al.  Comparison of Benefits on Myocardial Performance of Cellular Cardiomyoplasty with Skeletal Myoblasts and Fibroblasts , 2000, Cell transplantation.

[6]  C. Murry,et al.  Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. , 1999, Circulation.

[7]  S. Hunt.  Current status of cardiac transplantation. , 1998, JAMA.

[8]  A. Hagège,et al.  Can cellular transplantation improve function in doxorubicin-induced heart failure? , 1998, Circulation.

[9]  Johnny Huard,et al.  Development of Approaches to Improve Cell Survival in Myoblast Transfer Therapy , 1998, The Journal of cell biology.

[10]  G. Barlovatz-Meimon,et al.  Differential myogenicity of satellite cells isolated from extensor digitorum longus (EDL) and soleus rat muscles revealed in vitro , 1998, Cell and Tissue Research.

[11]  Doris A Taylor,et al.  Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation , 1998, Nature Medicine.

[12]  Doris A Taylor,et al.  Delivery of primary autologous skeletal myoblasts into rabbit heart by coronary infusion: a potential approach to myocardial repair. , 1997, Proceedings of the Association of American Physicians.

[13]  P. Singal,et al.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure. , 1997, The American journal of pathology.

[14]  M. Yacoub,et al.  Influence of preconditioning on rat heart subjected to prolonged cardioplegic arrest. , 1996, The Annals of thoracic surgery.

[15]  R. Hruban,et al.  Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. , 1996, Cell transplantation.

[16]  R. C. Chiu,et al.  Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. , 1995, The Annals of thoracic surgery.

[17]  P. Singal,et al.  Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. , 1995, Circulation.

[18]  G. Koh,et al.  Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. , 1995, The Journal of clinical investigation.

[19]  H. Blau,et al.  Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy , 1994, The Journal of cell biology.

[20]  G. Koh,et al.  Differentiation and long-term survival of C2C12 myoblast grafts in heart. , 1993, The Journal of clinical investigation.

[21]  E. A. Greene,et al.  Desmin is present in proliferating rat muscle satellite cells but not in bovine muscle satellite cells , 1991, Journal of cellular physiology.

[22]  F. Stockdale,et al.  Skeletal muscle satellite cell diversity: satellite cells form fibers of different types in cell culture. , 1991, Developmental biology.